MODUS THERAPEUTICS

MODUS THERAPEUTICS 2025 YEAR-END REPORT JANUARY–DECEMBER

JANUARY – DECEMBER 2025

YEAR-END REPORT IN BRIEF

The fourth quarter in figures

- The loss after tax amounted to TSEK 5 320 (4 713).
- The loss per share amounted to SEK 0,04 (0,13).
- The cash flow from current operations was negative in the amount of TSEK 5 003 (3 619).

The full year in figures

- The loss after tax amounted to TSEK 18 543 (15 545)
- The loss per share amounted to SEK 0,30 (0,43).
- The cash flow from current operations was negative in the amount of TSEK 18 075 (14 681).

Important events during the fourth quarter

- On 24 Oct 2025, Modus appointed Bergs Securities AB as Certified Adviser; Bergs assumes the role on 27 Oct 2025, with Svensk Kapitalmarknadsgranskning AB (SKMG) continuing until then.
- On 3 Nov 2025, Italian authorities approved the protocol amendment with dose selection for Part 2 of the Phase IIa CKD-anemia study; three sevuparin doses were set based on Part 1 (well tolerated), enabling repeat-dose/PoC initiation in Q4 2025 as planned.
- 10 Dec 2025: First patient dosed in Part 2 (PoC) of Modus' Phase IIa study in CKD anemia; repeat dosing initiated approximately one month after approval of the protocol amendment, in line with plan. Focus on safety and clinically relevant outcomes (including hemoglobin and hepcidin); the study is being conducted at two nephrology centers in Italy in collaboration with CRO Latis S.r.l. (total planned enrollment across Parts 1–2: ~50–60 patients).

Important events after the end of the period

- No significant events have occurred after the end of the period.



Financial overview

	2025	2024	2025	2024
The Group	**Oct 1–Dec 31**	**Oct 1–Dec 31**	**Jan 1–Dec 31**	**Jan 1–Dec 31**
Net sales, TSEK	-	-	-	-
Operating profit/loss, TSEK	-5 328	-4 846	-18 142	-15 838
Equity/Asset ratio, %	72%	44%	72%	44%
Cash equivalents, TSEK	11 373	4 379	11 373	4 379
Cash flow from operating activities, TSEK	-5 003	-3 619	-18 075	-14 681
Earnings per share, SEK	-0,04	-0,13	-0,30	-0,43
Shareholders equity, TSEK	9 071	2 137	9 071	2 137
Shareholders equity per share, SEK	0,07	0,06	0,14	0,06
R&D expense/operating expense, %	63%	59%	60%	57%
Average number of shares, 000'	121 628	35 939	62 649	35 939
Share price at the end of the period, SEK	0,30	1,81	0,30	1,81
Average number of employees	2,0	2,0	2,0	2,0

Definitions are provided on page 21.

"The Company" or "Modus" refers to the parent company Modus Therapeutics Holding AB with organization number 556851–9523.

"Subsidiary" or "Modus Therapeutics" refers to the subsidiary Modus Therapeutics AB with organization number 556669–2199.

2025 – A YEAR OF EXECUTION AND CLINICAL MOMENTUM

2025 marked an important transition for Modus where our focus moved from preparation and planning to tangible execution and clinical progress. Through successful financing activities during the year, we secured the resources needed to advance our lead program in chronic kidney disease (CKD) with anemia into its second part, an active proof-of-concept phase. The study Part 2 saw its first included patient in December and is at the end of February progressing according to plan.

In addition to advancing sevuparin with a clear priority on the CKD/anemia- indication, we are also continuing work on our additional value-creating opportunities in severe malaria and sepsis.

The progress made until now reflects a focused strategy true to our business model: to demonstrate the clinical potential of sevuparin, generate high-quality proof-of-concept data, and position Modus for the next stage of value creation through partnerships and further development.

CKD/anemia – entering proof-of-concept

During the year, we successfully completed Part 1 of our phase IIa study in CKD with anemia, as patient enrolment was finalized in July. As expected, study data confirmed a favorable safety profile for sevuparin at all dose levels. Based on these results, three dose levels were selected for Part 2, one for each category of CKD (3-5), and regulatory approval of the protocol amendment was granted by Italian authorities in November.

In December, the first patient was dosed in the repeated-dosing proof-of-concept phase – a major achievement for Modus and an important step forward for the program. This study part now enables us to evaluate sevuparin's effects on early hemoglobin signals, hepcidin and kidney-related biomarkers in patients with more advanced CKD and to generate the first clinical efficacy signals in this important indication. Following the initiation of Part 2 in December and the activation of both study sites at the nephrology centers in Verona and Pavia, patient enrolment is progressing according to plan.

Scientific validation and international recognition

During 2025, our scientific platform was further strengthened by new preclinical data from our collaboration research group around Professor Maura Poli at the university of Brescia, demonstrating that sevuparin improves both anemia and kidney disease related measures in a well-established CKD model. The data showed reduced fibrosis and biomarkers of tissue damage, both with sevuparin as monotherapy and when in combination with the clinical standard treatment erythropoietin (EPO), which further supports the multimodal and disease-modifying potential of sevuparin.

These results were presented at several leading international conferences, including BioIron in Montreal, the EHA Congress in Milan and the GAG Symposium in Italy, reinforcing Modus' position as a leading player in carbohydrate-based therapeutics and anemia in chronic inflammation.

Malaria and sepsis – further development opportunities

In parallel, we continued to broaden the clinical relevance of sevuparin through selected additional indications. In severe malaria, patient enrolment in the phase Ib SEVUSMART study

was completed in the first quarter, representing an important milestone for a program driven primarily through external collaboration with the lead investigator Professor Kathryn Maitland and her group at Imperial College London and non-dilutive funding. In 2026, the project plans to continue its exploration of avenues that would allow for further non-dilutive funding to support the next clinical research activities following the SEVUSMART study.

In sepsis, we are continuing to build on encouraging phase Ib results while further development is expected to be pursued primarily through business development and partnering activities, reflecting the clinical complexity and capital requirements of this indication. The importance of new sepsis treatments has become increasingly evident during 2025 as antimicrobial resistance (AMR) continues to rise globally. With an estimated one in six infections now caused by resistant bacteria, AMR and its consequences, including sepsis, have moved higher on the EU medical countermeasures agenda — reinforcing the long-term relevance of novel, mechanism-based approaches.

Looking ahead – a defining phase for Modus

As we enter 2026, Modus is approaching a critical inflection point with the ongoing Phase IIa proof-of-concept study in patients with CKD. Our primary focus remains on disciplined execution of Part 2 throughout 2026, with the ambition to generate initial proof-of-concept data by the end of 2026. Based on the financing completed in 2025, and assuming a successful exercise of the outstanding warrants in 2026, we expect to have funding in place to support the execution of this plan through the anticipated readout of the study.

In parallel, we will continue to advance structured partnering discussions, supported by our growing clinical and preclinical data package. Within severe malaria, we look forward to the reporting of results from the sponsor-led SEVUSMART study conducted by Imperial College London, and to jointly evaluating potential next development steps based on the scientific outcomes and available funding pathways. In sepsis, we remain committed to exploring strategic collaborations aligned with the complexity and scale of this indication.

With a streamlined organization, a strengthened financial position and a clear strategic focus, we believe Modus is well positioned to take the next value-creating steps. What differentiates Modus is how we execute this strategy — through long-standing scientific collaborations, a lean organizational structure and capital-efficient development built around trusted academic and industrial networks rather than large in-house organizations. Our objective is clear: to build clinical product value in sevuparin and to translate this into meaningful partnerships that can ultimately benefit patients, partners and shareholders alike.

On behalf of the company, I would like to sincerely thank our expert co-workers, collaborators and long-standing network of contracting organizations, as well as the patients participating in our clinical studies, for their continued trust and contribution. I would also like to thank our shareholders for their continued support. Your commitment enables us to advance sevuparin with focus, discipline and long-term ambition.

On behalf of the company, I would like to sincerely thank all our shareholders for their continued trust and support. Your commitment is fundamental to our ability to advance sevuparin and to pursue innovative treatments for patients with serious diseases and high unmet medical needs.

John Öhd, CEO, Modus Therapeutics

ABOUT MODUS THERAPEUTICS

Modus is developing sevuparin for patients with severe diseases and high unmet medical needs
Modus Therapeutics is a Swedish biotechnology company developing sevuparin, an innovative drug candidate with the potential to transform the treatment of diseases for which there are currently no effective therapeutic options. Our goal is to establish a new treatment paradigm and improve care for patients with serious and chronic illnesses.

Focus on anemia in chronic kidney disease (CKD)

In 2024, Modus took a decisive step by initiating a Phase IIa study of sevuparin in CKD-related anemia (approved by the Italian authorities in November 2023). Part 1 began in December 2024, and recruitment was completed on 8 July 2025 at two leading nephrology centers in Italy. Based on Part 1 data, three dose levels were selected for Part 2 on 1 August 2025, and the protocol amendment was submitted as planned. On 4 November 2025, Modus received regulatory approval from the Italian authorities for Part 2 of the study, which comprises repeated dosing and proof-of-concept in patients with CKD and anemia. In December 2025, the first patient was dosed in Part 2, in accordance with the company's timeline.

Anemia in CKD is a major global health issue that adversely affects quality of life and disease progression for millions of patients. Current treatment options are limited, and the need for new therapeutic solutions is significant. Sevuparin's ability to influence key mechanisms in the disease's pathophysiology makes it a promising candidate in this area.

Sevuparin is also being developed for acute inflammatory conditions

Beyond CKD, Modus is also exploring the potential of sevuparin in sepsis and severe malaria—both life-threatening conditions characterized by intense systemic inflammation. Previous research has indicated that sevuparin may exert a protective effect by modulating inflammation in malaria and sepsis. We are now evaluating the possibilities for further development in these areas.

Looking ahead – continued clinical and business development

With an ongoing Phase IIa study in CKD, a strong intellectual property portfolio, and a team with deep scientific expertise, Modus is well-positioned to advance to the next stage of its development. In 2025, we will focus on driving our clinical programs forward while actively exploring business development opportunities to maximize the value of sevuparin.

Sevuparin in short

Sevuparin, a heparinoid (a heparin-like molecule), treats conditions with acute systemic inflammation, such as sepsis, severe endotoxemia, severe malaria as well as states of anemia related to chronic inflammatory disease. Sevuparin is design with inflammation modifying properties without causing any significant blood-thinning. As a result, higher doses of Sevuparin can be administered compared to other heparinoids, allowing treatment of a broader range of conditions caused by severe inflammation.

Modus pipeline



CKD: *Chronic Kidney Disease. * In collaboration with Imperial College London and financed by grant from Wellcome.*

SEVUPARIN – A DRUG CANDIDATE WITH BROAD CLINICAL POTENTIAL

Modus Therapeutics is developing innovative treatments for patients suffering from serious diseases where current therapeutic options are limited. With our drug candidate sevuparin, we have the opportunity to target multiple core disease mechanisms simultaneously addressing significant unmet medical needs in chronic kidney disease (CKD) with anemia, severe malaria, and sepsis.

Inspired by the body's own biology

Sevuparin is a refined derivative of naturally occurring heparin molecules, known as heparan sulfates, which evolution has shaped to play essential roles in a range of biological processes—and thus in multiple disease states. Heparan sulfates are found on cell surfaces and within the extracellular matrix, acting as key regulators of inflammation, coagulation, hormonal signaling, cell growth, and immune defense.

Thanks to its structural similarity to these endogenous molecules, sevuparin can interact with and modulate these biological systems. Unlike conventional heparins, which have been used primarily as anticoagulants since the 1930s, sevuparin is engineered to retain the biological functions of native heparan sulfates while significantly reducing its blood-thinning effect. This allows for higher dosing without increased bleeding risk—enabling novel therapeutic applications in serious medical conditions (outlined below).

Focus on CKD with anemia and chronic inflammation

Our primary clinical development focus is the treatment of anemia in chronic kidney disease (CKD), a condition characterized by chronic inflammation and impaired iron metabolism that leads to reduced red blood cell production and diminished quality of life for patients. By targeting hepcidin—a central hormone in iron regulation—sevuparin has shown promising results in preclinical studies, improving both hemoglobin levels and kidney function.

Previous clinical trials have also confirmed a favorable safety profile for sevuparin in humans, providing a strong foundation for continued development in CKD/anemia—a field in urgent need of new and effective therapies.

Potential benefits in severe malaria and sepsis

Beyond CKD/anemia, sevuparin shows considerable promise in severe malaria and sepsis—two life-threatening conditions in which uncontrolled inflammation and vascular endothelial damage are key drivers of disease progression. By protecting the endothelium and neutralizing harmful inflammatory mediators, sevuparin may help reduce disease burden and improve survival in these critical illnesses.

With its unique biological profile—rooted in the body's own defense mechanisms—sevuparin stands out as an innovative drug candidate with the potential to transform the treatment landscape for multiple serious diseases. Modus Therapeutics is well positioned to advance this development and create both medical and commercial value.



MARKET OVERVIEW

With sevuparin, Modus is targeting three challenging indications—each with significant standalone potential.

Anemia in Chronic Kidney Disease (CKD)

One of the most serious complications of CKD is anemia, affecting approximately 25% of patients in stages 3–5—equivalent to over 4.5 million individuals in the U.S. alone. Anemia in CKD worsens disease progression and is linked to poor prognosis, higher rates of hospitalization, and increased mortality. Current treatments primarily rely on erythropoiesis-stimulating agents (ESA/EPO) and iron supplementation. However, a significant unmet need remains—particularly for patients who do not respond to treatment or where anemia is driven by alternative mechanisms.

Sevuparin is a novel, low-anticoagulant heparinoid with anti-inflammatory and hepcidin-lowering properties. Preclinical and clinical data show that sevuparin strongly downregulates hepcidin expression—a key regulator of iron metabolism—through the BMP/SMAD signaling cascade. In a CKD mouse model, sevuparin improved both hemoglobin levels and kidney function, while reducing serum hepcidin and markers of kidney injury and fibrosis. These data suggest that sevuparin may offer dual benefits in treating anemia and preserving kidney function in CKD.

The market potential is substantial. Modus, together with external analytics firm XPLICO, has identified an addressable market for sevuparin in CKD-associated anemia (stage 3–5) projected to include over 10 million patients across the seven major pharmaceutical markets (7MM) by 2038—representing a potential multi-billion-dollar opportunity. This is reflected in previous deals in the field, such as Akebia Therapeutics' partnership with Otsuka Holdings, and the market valuation of companies like Disc Medicine (NASDAQ: IRON), which stood at approximately USD 1.8 billion as of April 2025.

Severe Malaria

Severe malaria is a rapidly progressing, life-threatening condition caused by Plasmodium falciparum and closely resembles sepsis in its clinical presentation—featuring systemic inflammation, vascular injury, and multi-organ dysfunction. It primarily affects children under the age of five and is associated with a mortality rate of 10–20%, even with treatment. While intravenous artemisinin-based drugs are the standard of care, there are currently no approved adjunctive therapies targeting the underlying mechanisms responsible for the early, severe symptoms.

The global situation is further exacerbated by rising drug resistance, particularly in Africa and Southeast Asia, the spread of novel urban-

Anemia/CKD

1.4 million
deaths globally per year.

10 million
patients addressable market 2038.

Sepsis

11 million
deaths globally per year.

4 million
patients addressable market 2038.

Severe malaria

619 thousand
deaths globally per year.

80%
of deaths are children.

adapted mosquito vectors, and climate-related changes that increase the incidence and severity of malaria outbreaks.

Sevuparin has the potential to become a first-in-class adjunctive therapy by targeting the host's inflammatory response and microvascular dysfunction—key drivers in the pathogenesis of severe malaria. Its mechanism of action is independent of parasite resistance, making it particularly relevant in today's evolving therapeutic landscape.

Malaria remains one of the world's deadliest infectious diseases. According to WHO, there were 247 million malaria cases globally in 2021, resulting in 619,000 deaths—80% of which occurred in children under five. Africa accounts for 95% of malaria-related deaths, highlighting the urgent need for new treatment options.

There is growing international commitment to tackling malaria. For example, UNICEF and GAVI have entered into a procurement agreement with GSK for 18 million doses of the first malaria vaccine (RTS,S), valued at up to USD 170 million—demonstrating global willingness to invest in effective solutions. The market for malaria treatments is projected to grow beyond USD 3 billion by 2035, according to current market analyses.

Beyond the global disease burden, malaria drug development also benefits from regulatory incentives in high-income countries. In the U.S., malaria is classified as a rare disease (fewer than 2,000 cases annually—primarily among travelers), making sevuparin eligible for Orphan Drug Designation by the FDA. This would grant seven years of market exclusivity, reduced regulatory fees, and enhanced support. Examples of approved orphan therapies include intravenous artemisinin derivatives, now marketed as orphan drugs in both the U.S. and EU.

Malaria treatments may also qualify for the FDA's Priority Review Voucher (PRV) program, which awards a transferable voucher for accelerated review of another drug upon approval. PRVs have recently been sold for over USD 100 million, underscoring their considerable commercial value.

With its innovative mechanism of action, robust safety profile, and potential to combine clinical efficacy with commercial appeal, sevuparin is well-positioned to become an important future asset in the global fight against severe malaria—from both a public health and investment standpoint.

Sepsis

Sepsis is a life-threatening condition caused by the body's extreme response to an infection, resulting in injury to its own tissues and organs. According to the World Health Organization (WHO), sepsis was linked to an estimated 11 million deaths globally in 2017—about 20% of all global deaths that year. In the U.S., approximately 2 million cases occur annually, and in Sweden, sepsis accounts for more cases than the four most common cancer types combined.

Septic shock, the most severe form of sepsis, is among the leading causes of death in intensive care units worldwide, with an estimated mortality rate of 30%. Despite its severity, there are currently no approved therapies specifically indicated for sepsis or septic shock. Treatment typically focuses on addressing the underlying infection with antibiotics and stabilizing the patient through intensive care interventions. The lack of targeted therapies has kept sepsis among the most resource-intensive conditions in healthcare—with estimated annual costs of USD 22 billion in the U.S. alone, a USD 5 billion increase since 2012.

Sepsis is classified as a high-priority condition (vital indication), enabling potential future treatments to command premium pricing. Modus and XPLICO have identified the target market for sevuparin in sepsis as patients with septic shock—approximately 700,000 individuals across the seven major pharmaceutical markets (7MM). This group represents a potential annual sales opportunity of around USD 6 billion by 2038. An even broader market potential exists in the general sepsis population, which is approximately five times larger.

BUSINESS MODEL & COLLABORATIONS

Business model
Given that sevuparin has the potential to be the first and only treatment specifically targeting the conditions Modus is pursuing, the company expects significant market interest in sevuparin following favorable clinical trial outcomes.

Modus' business model is to independently advance the development of sevuparin through Phase IIa proof-of-concept trials—both in anemia associated with chronic kidney disease and in sepsis. The company also aims to continue progress in severe malaria through advantageous collaborative frameworks.

Based on data from these studies, Modus intends to either initiate a sale of the company or license out sevuparin, with the ultimate goal of establishing the drug on the market. Should market interest not be sufficiently strong based on the Phase IIa data, a potential acquisition or licensing agreement may be revisited at a later stage—such as toward the end of Phase IIb trials. At that point, a larger commercial partner would be able to drive Phase III development in a manner best aligned with their operational and strategic capabilities. According to the current development plan, a market launch and New Drug Application (NDA) could be feasible by 2030.

In general, market authorization requires two large Phase III studies with more than 1,000 patients over an extended time frame. However, treatments that address areas of high unmet need may qualify for regulatory flexibilities. A number of FDA and EMA programs may be applicable to sevuparin, should future clinical trials prove successful. For instance, Modus could be granted Accelerated Approval based on positive Phase IIb or early Phase III results, particularly if improvement in sepsis or severe malaria symptoms can be demonstrated. Such approval would allow earlier market entry for sevuparin while confirmatory Phase III trials are ongoing.

There is also the potential to receive Breakthrough Therapy Designation, which could facilitate the clinical development and regulatory review process, including acceptance of alternative clinical endpoints.

Timeline in traditional drug development

In non-endemic markets such as the US and EU, malaria/severe malaria may be classified as an orphan disease due to its relative rarity, primarily affecting returning travelers from endemic regions. Orphan Drug Designation can provide market exclusivity, regulatory support, and access to a Priority Review Voucher (PRV), enabling faster regulatory review and carrying significant commercial value.

A final scenario could involve Modus continuing development through the completion of Phase III trials, after which a licensing or acquisition strategy would again be pursued. Modus is also prepared to bring sevuparin to market independently, potentially through a network of geographically defined commercial partnerships with local sales partners.

Collaborations
Modus has an ongoing research collaboration with Professor Maura Poli and her team at the University of Brescia, which has been instrumental in establishing the therapeutic focus on anemia and kidney disease within Modus' pipeline.

An additional collaboration was initiated in 2021 with Imperial College London to investigate sevuparin's potential as an adjunctive treatment in severe malaria. Under this collaboration, Modus supplies sevuparin for the various phases of clinical trials in patients with severe malaria. The program is funded by research grants awarded to the study sponsor, Imperial College London, by Wellcome.

Accelerated approval
Granted by both the EMA and FDA to enable faster approval of a drug compared to the standard lengthy regulatory process. The FDA will re-evaluate the application and provide a decision within 60 days of submission. Typically granted for indications with high unmet medical needs.

Breakthrough Therapy
A designation that can expedite the development and review of drugs intended for serious medical conditions, where early clinical evidence indicates a substantial improvement over existing treatments or achievement of one or more clinically meaningful endpoints (endpoint = study objective or goal).

Orphan Drug Designation (ODD)
Granted by FDA and EMA for treatments targeting rare diseases, offering benefits such as market exclusivity and regulatory support, including fee waivers. In the US, an approved ODD may also qualify for a PRV, offering commercial and strategic advantages.

DEVELOPMENT OF PROFIT AND FINANCIAL POSITION

Fourth quarter

Operating profit/loss
The operating loss for July–December 2025 amounted to 5 328 (4 846) TSEK. Research and development expenses increased by 515 TSEK versus the same period last year, primarily driven by clinical activities—including the ongoing Phase IIa study.

Cash flow, investments, and financial position
At the beginning of the period, cash and cash equivalents amounted to TSEK 16 534, and at the end of the period to TSEK 11 373. Cash flow from current operations was to the amount of TSEK -5 003 (-3 916), of which changes in working capital amounted to a TSEK 317 (1 095). The cash flow from financing activities amounted to TSEK -158(0). The total cash flow amounted to a TSEK -5 161 (-3 619).

Full year

Operating profit/loss
The operating loss for the period January–December 2025 amounted to 18 142 (15 838) TSEK. Research and development expenses increased by 1 783 TSEK compared to the same period last year, primarily driven by clinical activities—including the ongoing Phase IIa study–and entry into the national phase for filed patent applications.

Cash flow, investments, and financial position
At the beginning of the period, cash and cash equivalents amounted to TSEK 4 379, and at the end of the period to TSEK 11 373. Cash flow from current operations was to the amount of TSEK -18 075 (-14 681), of which changes in working capital amounted to a TSEK 59 (865). The cash flow from financing activities amounted to TSEK 25 069 (0). The total cash flow amounted to a TSEK 6 993 (-14 681).

Important events during the fourth quarter

Change of Certified Adviser to Bergs Securities AB

On 24 October 2025, Modus announced that it had entered into an agreement with Bergs Securities AB to act as its Certified Adviser. Bergs Securities will assume the role on 27 October 2025. Until that date, Svensk Kapitalmarknadsgranskning AB continues as the company's Certified Adviser.

Modus receives regulatory approval for Part 2 of the Phase IIa study in CKD with anemia

On 3 November 2025, Italian authorities approved Modus' dose selection for Part 2 (repeat dosing; proof-of-concept) of its ongoing Phase IIa study evaluating sevuparin in patients with CKD with anemia. This approval enables initiation of Part 2 in Q4 2025, in line with prior guidance. The approved amendment specifies three sevuparin doses for patients with CKD stages 3–5, based on single-dose data from Part 1 in which sevuparin was well tolerated with no discontinuations or clinically meaningful safety signals; data also indicate no dose adjustment is required for CKD stages 1–2. The study is conducted at two leading nephrology centers in Italy (Verona and Pavia) together with CRO partner Latis S.r.l. This milestone advances Modus' CKD program and allows evaluation of sevuparin's clinical potential under repeat dosing. Next steps include site activation and patient screening for Part 2, alongside ongoing business-development activities.

First patient dosed in Part 2 of Modus Therapeutics' Phase IIa study in chronic kidney disease with anemia

On 10 December 2025, Modus announced that the first patient had been dosed in Part 2 (repeat dosing; proof-of-concept) of its ongoing Phase IIa study evaluating sevuparin in chronic kidney disease (CKD) with anemia. Part 2 follows a planned protocol amendment with final dose selection based on data from Part 1 (single dose) and was initiated approximately one month after regulatory approval, in line with the company's plan. This part of the study focuses on safety and clinically relevant outcomes, including hemoglobin and hepcidin, as well as other kidney- and blood-related biomarkers in patients with advanced CKD and anemia. The study is being conducted at two leading nephrology centers in Italy (Verona and Pavia) in collaboration with CRO partner Latis S.r.l., with a total planned enrollment of approximately 50–60 patients across Parts 1–2. The initiation represents an important milestone for Modus' CKD program and enables continued evaluation of sevuparin's clinical potential under repeat dosing.

Important events after the end of the period

No significant events have occurred after the end of the period.

OTHER DISCLOSURES

Ownership structure
At the end of the fourth quarter 2025, there were 1 394 shareholders in Modus Therapeutics Holding AB, of which the three largest shareholders owned 66,1% of the capital and votes. The total number of shares was 121 628 493. The largest shareholders, on December 31, 2025, were KDventures, Hans Wigzell och Avanza Pension.

Parent Company
Modus Therapeutics Holding AB, corporate identity number 556851-9523 is the parent company of the group and was formed in 2011. The actual operations are conducted by the fully owned subsidiary Modus Therapeutics AB. As per December 31 2025, there were two employees, the CEO and the groups finance department. The company's main task is of a financial nature to fund the group's operational activities. Net sales for the period reached TSEK 740 (740). The loss for the period amounted to TSEK 14 246 (14 968). The company's net sales consist of invoiced consultancy fees to the fully owned subsidiary Modus Therapeutics AB.

Employees
The number of employees at the end of the period was 2 (2).

Proposed dividend
In view of the Modus financial position and negative earnings, the company's Board of Directors does not intend to propose any dividend before the company generates long term sustainable profit and positive cash flow.

Annual General Meeting and Annual Report
The Annual General Meeting will be held on May 28, 2025. The annual report for the financial year 2026 will be available for download via the Company's website (www.modustx.com) on April 15, 2026.

Financing
The Board regularly reviews the Company's liquidity position and projected cash flows to ensure that Modus has sufficient resources to execute its approved clinical development plan.

During 2025, the Company strengthened its financial position through a fully secured rights issue of units amounting to approximately SEK 28.3 million before transaction costs, which was oversubscribed. In addition, a directed compensation issue to guarantors of approximately SEK 1.7 million was completed. After transaction costs of approximately SEK 4.5 million, the net proceeds amounted to approximately SEK 25.5 million, of which approximately SEK 5.4 million related to the offsetting of loans and accrued interest. Net proceeds in the form of new capital thus amounted to approximately SEK 20.1 million.

Together with bridge financing utilized during the year from the Company's largest shareholder, the total funding provided amounted to approximately SEK 25.1 million. The capital is primarily being used to finance the ongoing Phase IIa study of sevuparin in chronic kidney disease (CKD)-related anemia, including the execution of Part 2 (proof-of-concept).

As of 31 December 2025, the Group's cash and cash equivalents amounted to SEK 11.4 million. Subject to full exercise of warrants of series TO 2026, the Company may be provided with additional proceeds of approximately SEK 10.0 million before transaction costs. In the Board's assessment, the available financing, including a full exercise of TO 2026, provides the Company with funding to support operations through the end of 2026.

The Company continuously evaluates additional financing opportunities to enable the completion of the clinical development of sevuparin. There can be no assurance that sufficient capital will be obtained on favorable terms or at all; however, the Board assesses that the Company has good prospects for securing continued financing given the progress of the clinical development. If the capital raise described above is not completed, a material uncertainty exists regarding the Group's ability to continue as a going concern.

Financial risks
Modus operates in a global environment where external factors increasingly affect the conditions for capital raising. Geopolitical events such as Russia's invasion of Ukraine, increased trade barriers, inflation, interest rate hikes, and a generally deteriorated investment climate in the capital markets create uncertainty for research-intensive companies within life sciences. These factors may affect Modus' ability to secure necessary financing on favorable terms in a timely manner. In addition, unforeseen delays in clinical development could lead to further pressure on the company's refinancing needs. The Board closely monitors developments, and Modus is working intensively to minimize the impact of crises and other external circumstances.

Risks and uncertainties
Modus Therapeutics risks and uncertainties include, but are not limited to, risks related to drug development and financial risks such as future financing. Further information on the Company's risk exposure can be found on page 25 of Modus Therapeutics Holding's annual report for 2024.



Consolidated summary income statement

TSEK	2025 Oct 1–Dec 31	2024 Oct 1–Dec 31	2025 Jan 1–Dec 31	2024 Jan 1–Dec 31
Net sales	-	-	-	-
Research and development costs	-3 368	-2 853	-10 850	-9 067
Administration costs	-1 961	-1 978	-7 316	-6 727
Other operating income	1	-15	24	-44
Operating profit/loss	**-5 328**	**-4 846**	**-18 142**	**-15 838**
Net interest income	8	133	-401	293
Profit/loss after financial items	**-5 320**	**-4 713**	**-18 543**	**-15 545**
Income tax	-	-	-	-
PROFIT/LOSS FOR THE PERIOD	**-5 320**	**-4 713**	**-18 543**	**-15 545**
Earnings per share before and after dilution (SEK)	-0,04	-0,13	-0,30	-0,43
Net profit/loss attributable to: Parent company shareholders	**-5 320**	**-4 713**	**-18 543**	**-15 545**

Consolidated summary balance sheet

	2025	2024
TSEK	**Dec 31**	**Dec 31**
Assets		
Fixed Assets		
Other financial fixed assets	-	52
Total fixed assets	**-**	**52**
Current assets		
Other receivables	1 313	453
Cash equivalents	11 373	4 379
Total current assets	**12 686**	**4 832**
TOTAL ASSETS	**12 686**	**4 884**
Equity and liabilities		
Share capital	7 298	2 156
Additional paid-in capital	353 235	332 899
Retained earnings including net loss for the period	-351 462	-332 919
Total equity attributable to parent company shareholders	**9 071**	**2 137**
Current liabilities		
Interest-bearing liabilities	-	-
Accounts payable	2 274	1 555
Other liabilities	175	229
Accrued expenses and deferred income	1 166	963
Total current liabilities	**3 615**	**2 747**
TOTAL EQUITY AND LIABILITIES	**12 686**	**4 884**

Consolidated change in shareholder's equity in summary

TSEK	2025 Oct 1–Dec 31	2024 Oct 1–Dec 31	2025 Jan 1–Dec 31	2024 Jan 1–Dec 31
Opening balance equity	**14 549**	**6 849**	**2 137**	**17 681**
Profit/loss for the period	-5 320	-4 713	-18 543	-15 545
Total comprehensive income	**-5 320**	**-4 713**	**-18 543**	**-15 545**
New issue of shares		-	29 991	-
Costs for new issue	-158	-	-4 514	-
Total transactions with shareholders	**- 158**	**-**	**25 477**	**-**
CLOSING BALANCE EQUITY	**9 071**	**- 2 137**	**-9 071**	**2 137**

The equity is assignable the shareholders of the parent company.

Consolidated cash flow statement in summary

TSEK	2025 Oct 1–Dec 31	2024 Oct 1–Dec 31	2025 Jan 1–Dec 31	2024 Jan 1–Dec 30
Operating activities				
Operating profit/loss	-5 329	-4 846	-18 142	-15 838
Interest received	9	132	9	292
Interest paid	0	0	-1	-
Cash flow from operating activities before changes in working capital	**-5 320**	**-4 714**	**- 18 134**	**-15 546**
Changes in working capital	-317	1 095	59	865
Cash flow from operating activities	**-5 003**	**-3 619**	**-18 075**	**-14 681**
Cash flow from investment activities	-	-	-	-
Cash flow from financing activities	-158	-	25 069	-
Cash flow for the period	**-5 161**	**-3 619**	**6 993**	**-14 681**
Cash equivalents at the beginning of the period	16 534	7 999	4 379	19 060
Changes in cash equivalents	-5 161	-3 620	6 993	-14 681
CASH EQUIVALENTS AT THE END OF THE PERIOD	**11 373**	**4 379**	**11 373**	**4 379**

Parent company income statement in summary

TSEK	2025 Oct 1–Dec 31	2024 Oct 1–Dec 31	2025 Jan 1–Dec 31	2024 Jan 1–Dec 31
Net sales	185	185	740	740
Research and development costs	-390	-365	-1 516	-1 450
Administration costs	-1 789	-1 768	-6 706	-6 110
Other operating expenses	-	-	-3	-1
Operating profit/loss	**-1 994**	**-1 948**	**-7 485**	**-6 821**
Net interest income	8	133	-401	293
Profit/loss after financial items	**-1 986**	**-1 815**	**-7 886**	**-6 528**
Appropriation	-6 360	-8 440	-6 360	-8 440
Income tax expense	-	-	-	-
PROFIT/LOSS FOR THE PERIOD	**-8 346**	**-10 245**	**-14 246**	**-14 968**

Parent company balance sheet

TSEK	2025 Dec 31	2024 Dec 31
Assets		
Non-current assets		
Financial assets	70 000	70 052
Total non-current assets	**70 000**	**70 052**
Current assets		
Other receivables	176	162
Cash equivalents	11 004	2 519
Total current assets	**11 180**	**2 681**
TOTAL ASSETS	**81 180**	**72 733**
Equity and liabilities		
Restricted equity		
Share capital	7 298	2 156
Non-restricted equity		
Share premium reserve	353 109	332 773
Retained earnings	- 277 759	-262 791
Profit/loss for the period	-14 246	-14 968
TOTAL EQUITY	**68 401**	**57 170**

TSEK	2025 Dec 31	2024 Dec 31
Current liabilities		
Interest-bearing liabilities	-	-
Accounts payable	320	144
Liabilities to Group companies	11 401	14 366
Other liabilities	175	229
Accrued expenses and deferred income	883	823
Total current liabilities	**12 779**	**15 562**
TOTAL EQUITY AND LIABILITIES	**81 180**	**72 733**

NOTES

Note 1. Accounting principles

Modus Therapeutics Holding AB's consolidated accounts have been prepared in accordance with the annual accounts act and the Swedish accounting standards board's general advice BFNAR 2012: 1 Annual Report and the Consolidated Financial Statements (K3). The interim report for the company has been prepared in accordance with chapter 9 of the annual accounts act and the same accounting principles have been applied as in the most recent annual report for 2024 note 1.

Note 2. Transactions with related parties

During the period, the parent company Modus Therapeutics Holding AB has invoiced TSEK 740 (740) to the fully owned subsidiary Modus therapeutics AB, which corresponds to 100% of the parent company's turnover for the period. During the reporting period there were no other transactions with related parties that had any material impact on the group or parent company's position and earnings.

Note 3. Incentive program

There are no outstanding share related incentive programs in the Company.

Note 4. Equity

The share capital of the Parent Company consists only of fully paid ordinary shares with a nominal (quota value) of SEK 0,06/share. The company has 121 628 493 shares.

	2025	2024
Shares/SEK	Jan 1 – Dec 31	Jan 1 – Dec 31
Subscribed and paid shares:		
At the beginning of the period	35 938 899	35 939 899
Share merger	-	-
Offset issue	-	-
Rights issue	85 689 594	-
Subscribed and paid shares	**121 628 493**	**35 938 899**
Shares for sharebased payments	-	-
SUM AT THE END OF THE PERIOD	**7 297 710**	**2 156 334**

SIGNATURES

The Board of Directors and the CEO provide their assurance that this interim report provides an accurate view of the operations, position and earning of the group and the parent company, and that it also describes the principal risks and uncertainties faced by the parent company and the companies included within the group.

This report has been prepared in both Swedish and English. In the event of discrepancies between the versions, it is the Swedish version that applies.

This interim report has not been subject to review by the Company's auditors.

Viktor Drvota,
Chairman of the board

Ellen K. Donnelly,
Board member

Johan Dighed,
Board member

John Öhd,
CEO

Financial Calendar

Annual Report 2025	April 15, 2026
Interim Report for the first quarter 2026	May 26, 2026
Annual General Meeting 2026	May 28, 2026
Interim Report for the second quarter 2026	August 26, 2026
Interim Report for the third quarter 2026	November 24, 2026
Year-End Report 2026	February 24, 2027

QUARTERLY OVERVIEW

	2025				2024				2023
The Group	**Q4**	**Q3**	**Q2**	**Q1**	**Q4**	**Q3**	**Q2**	**Q1**	**Q4**
Net sales, TSEK	-	-	-	-	-	-	-	-	-
Operating profit, TSEK	-5 328	-4 226	-5 873	-2 715	-4 846	-2 989	-4 804	-3 199	-3 771
Equity/Asset ratio, %	72%	83%	-197%	-11%	44%	80%	79%	91%	88%
Cash equivalents, TSEK	11 373	16 534	1 897	5 320	4 379	7 999	11 971	15 395	19 060
Cashflow from operating activities, TSEK	-5 003	-5 590	-3 423	-4 059	-3 619	-3 971	-3 424	-3 665	-3 127
Earnings per share (before and after dilution), SEK	-0,04	-0,08	-0,17	-0,08	-0,13	-0,08	-0,13	-0,09	-0,18
Shareholder's equity at the end of the period, TSEK	9 071	14 549	-6 744	-678	2 137	6 851	9 839	14 577	17 682
Shareholder's equity per share, SEK	-0,07	-0,26	-0,19	-0,02	0,06	0,19	0,27	0,41	0,78
R&D expense/operating expense, %	63%	62%	62%	45%	59%	61%	61%	46%	33%
Average number of shares, 000'	121 628	56 220	35 939	35 939	35 939	35 939	35 939	35 939	22 626
Share price at the end of the period, SEK	0,3	0,5	1,20	1,33	1,81	1,65	1,03	1,14	1,74
Average number of employees	2,0	2,0	2,0	2,0	2,0	2,0	2,0	2,0	2,0

Definitions

Financial key ratio

Operating profit
Operating income less operating expenses.

Equity/Asset ratio
Equity at the end of the period divided by total assets at the end of the period.

Earnings per share for the period before dilution
Profit for the period divided by the average number of shares before dilution.

Earnings per share for the period after dilution
Profit for the period divided by the number of shares after dilution. Earnings per share after dilution is the same as before dilution because potential ordinary shares do not cause dilution.

Shareholder's equity per share
Equity divided by average number of shares.

R&D expense/operating expense, %
Research and development costs divided by total operating costs.

Number of employees (average)
Weighted average number of employees in the relevant period.

LEADERSHIP TEAM & BOARD

John Öhd, M.D., PhD

CEO since 2020 and previously CMO since 2018.

Born: 1971

Education and experience: MD, PhD. John Öhd has extensive experience in drug development and has previously worked in several different indication areas, including CNS, cancer and blood diseases. His previous qualifications include leadership positions within the research organizations of AstraZeneca and Shire and as Chief Medical Officer at the biotechnology company Medivir.

Other current roles: Board Member at Umecrine Cognition AB, SVF Vaccines AB and Boost Pharma.

Holdings: 3 260 591 shares.

Claes Lindblad

CFO since 2021.

Born: 1967

Education and experience: Master of Sciences in Chemical and administrative sciences from university of Karlstad. Claes Lindblad has over 25 years of broad experience from leading positions in life science. He has previously been CFO of the Medtech company OssDsign, where he led the company's financial and administrative functions and played a key role in the company's listing on Nasdaq First North Growth Market 2019. Before that, he has held several senior positions, including Country manager for the global and market leading Medtec company ConvaTec, and in the role of Sales director for the OTC and generic portfolio at Nycomed / Takeda.

Holdings: 79 056 shares.

Viktor Drvota, M.D, PhD

Chairman since 2016.

Born: 1965

Education and experience: MD, PhD, Assoc Prof in Cardiology at Karolinska Institute. Viktor Drvota has over 18 years' experience from venture capital in life sciences. He was responsible for life science at SEB Venture Capital 2002–2016 and has many years of experience of board duties in biotech and medtech companies.

Other current roles: CEO of KDventures. Chairman of the board at Modus Therapeutics AB, Modus Therapeutics Holding AB, Umecrine Cognition AB and KDev Investments AB. Board member at UC Research AB, Dilafor AB and Dilafor Incentive AB. Deputy board member at Promimic AB and Svenska Vaccinfabriken Produktion AB.

Holdings: 0.

Independent in relation to the Company and company management but dependent in relation to the Company's major shareholders.

Johan Dighed

Board Member since September 2024.

Born: 1973

Education and experience: Master of Laws from Lund University. Johan Dighed has over 20 years' experience in financial and business law including positions as Head of Legal with the German bank SEB AG and legal counsel with SEB AB. Prior to joining the financial sector he worked with the international law firm Baker & McKenzie and in the Swedish Judiciary.

Other current roles: Deputy CEO and general counsel at KDventures. Board assignments in KDev Investments AB, KDev Invest Consulting AB, KCIF Fund Management, AnaCardio AB, AnaCardio R&D AB, AnaCardio Holding AB, KD Incentive AB, Modus Therapetuics AB, Pharmnovo and Promimic AB (publ).

Holdings: 0.

Independent in relation to the Company and company management but dependent in relation to the Company's major shareholders.

Ellen K. Donnelly, PhD

Board Member since 2020.

Born: 1974

Education and experience: PhD in Neuroscience from the Yale School of Medicine. Donnelly has extensive experience from leadership positions within Life Science, including as former CEO of Modus, Abliva and senior positions within Pfizer and Combinato Rx. Ellen Donnelly was previously CEO of Epigenetics Division and Juvenescence and management consultant for MEDACorp / Leerink and Swann Strategic Advisors.

Other current roles: CEO of Neumirna Therapeutics, Board member of Alzecure Pharma AB.

Holdings: 195 073 shares.

Independent in relation to the Company, the Company management and the Company's major shareholders.

MODUS THERAPEUTICS

Olof Palmes gata 29 IV,
111 22 Stockholm, Sweden

+46 (0)8-501 370 00
info@modustx.com
www.modustx.com

Contact

John Öhd, CEO
+46 (0)70-744 80 97
john.ohd@modustx.com

Claes Lindblad,
CFO & Head of IR
+46 (0)70-246 75 54
claes.lindblad@modustx.com